Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00305487
Collaborator
(none)
660
71
7
9.3
1.3

Study Details

Study Description

Brief Summary

The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).

Condition or Disease Intervention/Treatment Phase
  • Drug: Ciclesonide nasal spray
Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age
Study Start Date :
Mar 1, 2006
Actual Primary Completion Date :
Oct 1, 2006
Actual Study Completion Date :
Oct 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Average of morning and evening parent/caregiver reported reflective total nasal symptoms score over the two weeks of treatment []

Secondary Outcome Measures

  1. Physician assessment of nasal symptoms score at endpoint []

  2. average of morning and evening parent/caregiver reported instantaneous total nasal symptom score over the two weeks of treatment []

  3. safety []

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 11 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Main Inclusion Criteria:
  • Written informed consent

  • General good health other than seasonal allergic rhinitis

  • Positive standard skin prick test

Main Exclusion Criteria:
  • Pregnancy, nursing, or plans to become pregnant or donate gametes for in vitro fertilization

  • Participation in any investigational drug trial within the 30 days preceding the Screening Visit

  • A known hypersensitivity to any corticosteroid or any of the ingredients in the study drug formulation

  • Plans to travel outside the study area (the known pollen area for the investigative site) for 24 hours or more during the final 7 days of the baseline period

  • Plans to travel outside the study area (the known pollen area for the investigative site) for more than 2 consecutive days OR more than 3 days total during the treatment period

  • Use of any prohibited concomitant medications

  • Non-vaccinated exposure to or active infection with chickenpox or measles within the 21 days preceding the Screening Visit

  • Use of antiepileptic drugs for epilepsy within 30 days of the Screening Visit

  • Study participation by more than one patient from the same household

Contacts and Locations

Locations

Site City State Country Postal Code
1 Altana Pharma/Nycomed Birmingham Alabama United States 35235
2 Altana Pharma/Nycomed Hot Springs Arkansas United States 71913
3 Altana Pharma/Nycomed Costa Mesa California United States 92626
4 Altana Pharma/Nycomed Huntington Beach California United States 92647
5 Altana Pharma/Nycomed Long Beach California United States 90806
6 Altana Pharma/Nycomed Los Alamitos California United States 90720
7 Altana Pharma/Nycomed Mission Viejo California United States 92691
8 Altana Pharma/Nycomed Orange California United States 92868
9 Altana Pharma/Nycomed Roseville California United States 95678
10 Altana Pharma/Nycomed San Diego California United States 92120
11 Altana Pharma/Nycomed San Diego California United States 92123
12 Altana Pharma/Nycomed San Jose California United States 95117
13 Altana Pharma/Nycomed Stockton California United States 95207
14 Altana Pharma/Nycomed Colorado Springs Colorado United States 80907
15 Altana Pharma/Nycomed Denver Colorado United States 80230
16 Altana Pharma/Nycomed Englewood Colorado United States 80112
17 Altana Pharma/Nycomed Lakewood, CO Colorado United States 80401
18 Altana Pharma/Nycomed Atlanta Georgia United States 30342
19 Altana Pharma/Nycomed Gainesville Georgia United States 30501
20 Altana Pharma/Nycomed Savannah Georgia United States 31406
21 Altana Pharma/Nycomed Woodstock, GA Georgia United States 30188
22 Altana Pharma/Nycomed Normal Illinois United States 61761
23 Altana Pharma/Nycomed Indianapolis Indiana United States 46208
24 Altana Pharma/Nycomed Overland Park Kansas United States 66211
25 Altana Pharma/Nycomed Louisville, KY Kentucky United States 40215
26 Altana Pharma/Nycomed Metairie Louisiana United States 70006
27 Altana Pharma/Nycomed Shreveport Louisiana United States 71105
28 Altana Pharma/Nycomed Bethesda Maryland United States 20814
29 Altana Pharma/Nycomed North Dartmouth Massachusetts United States 02747
30 Altana Pharma/Nycomed Minneapolis Minnesota United States 55402
31 Altana Pharma/Nycomed Jefferson City Missouri United States 65109
32 Altana Pharma/Nycomed Rolla Missouri United States 65401
33 Altana Pharma/Nycomed St. Louis Missouri United States 63141
34 Altana Pharma/Nycomed Lincoln, NE Nebraska United States 68505
35 Altana Pharma/Nycomed Papillion Nebraska United States 68046
36 Altana Pharma/Nycomed Brick New Jersey United States 08724
37 Altana Pharma/Nycomed Forked River New Jersey United States 08731
38 Altana Pharma/Nycomed Red Bank New Jersey United States 07701
39 Altana Pharma/Nycomed Skillman New Jersey United States 08558
40 Altana Pharma/Nycomed Warren New Jersey United States 07059
41 Altana Pharma/Nycomed Rochester, NY New York United States 14618
42 Altana Pharma/Nycomed Rockville Centre New York United States 11570
43 Altana Pharma/Nycomed Raleigh North Carolina United States 27607
44 Altana Pharma/Nycomed Cincinnati, OH Ohio United States 45231
45 Altana Pharma/Nycomed Cincinnati Ohio United States 45219
46 Altana Pharma/Nycomed Ashland Oregon United States 97520
47 Altana Pharma/Nycomed Lake Oswego Oregon United States 97035
48 Altana Pharma/Nycomed Medford, OR Oregon United States 97504
49 Altana Pharma/Nycomed Portland Oregon United States 97213
50 Altana Pharma/Nycomed Blue Bell Pennsylvania United States 19422
51 Altana Pharma/Nycomed Eerie Pennsylvania United States 16506
52 Altana Pharma/Nycomed Pittsburgh Pennsylvania United States 15202
53 Altana Pharma/Nycomed Pittsburgh Pennsylvania United States 15241
54 Altana Pharma/Nycomed Upland Pennsylvania United States 19013
55 Altana Pharma/Nycomed Charleston, SC South Carolina United States 29407
56 Altana Pharma/Nycomed Charleston South Carolina United States 29414
57 Altana Pharma/Nycomed Germantown Tennessee United States 38138
58 Altana Pharma/Nycomed Jackson Tennessee United States 38301
59 Altana Pharma/Nycomed Austin Texas United States 78731
60 Altana Pharma/Nycomed Austin Texas United States 78750
61 Altana Pharma/Nycomed Dallas Texas United States 75231
62 Altana Pharma/Nycomed El Paso Texas United States 79925
63 Altana Pharma/Nycomed Kerrville Texas United States 78028
64 Altana Pharma/Nycomed New Braunfels Texas United States 78130
65 Altana Pharma/Nycomed San Antonio Texas United States 78229
66 Altana Pharma/Nycomed Salt Lake City Utah United States 84037
67 Altana Pharma/Nycomed South Burlington Vermont United States 05403
68 Altana Pharma/Nycomed Burke Virginia United States 22015
69 Altana Pharma/Nycomed Charlottesville Virginia United States 22911
70 Altana Pharma/Nycomed Richmond Virginia United States 23226
71 Altana Pharma/Nycomed Milwaukee Wisconsin United States 53209

Sponsors and Collaborators

  • AstraZeneca

Investigators

  • Study Director: AstraZeneca AstraZeneca, AstraZeneca

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00305487
Other Study ID Numbers:
  • BY9010/M1-417
First Posted:
Mar 22, 2006
Last Update Posted:
Nov 30, 2016
Last Verified:
Oct 1, 2016

Study Results

No Results Posted as of Nov 30, 2016